Sinopep-Allsino Biopharmaceutical Co. Ltd. A
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was… Read more
Market Cap & Net Worth: Sinopep-Allsino Biopharmaceutical Co. Ltd. A (688076)
Sinopep-Allsino Biopharmaceutical Co. Ltd. A (SHG:688076) has a market capitalization of $1.38 Billion (CN¥10.14 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #8203 globally and #1508 in its home market, demonstrating a -1.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinopep-Allsino Biopharmaceutical Co. Ltd. A's stock price CN¥32.08 by its total outstanding shares 316051897 (316.05 Million).
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap History: 2021 to 2026
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market capitalization history from 2021 to 2026. Data shows change from $1.75 Billion to $1.38 Billion (-16.40% CAGR).
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinopep-Allsino Biopharmaceutical Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.38x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 1.38 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
5.53x
Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap is 5.53 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.75 Billion | $643.87 Million | $115.39 Million | 2.71x | 15.13x |
| 2022 | $974.68 Million | $651.29 Million | $129.11 Million | 1.50x | 7.55x |
| 2023 | $1.92 Billion | $1.03 Billion | $162.94 Million | 1.86x | 11.79x |
| 2024 | $2.24 Billion | $1.62 Billion | $404.39 Million | 1.38x | 5.53x |
Competitor Companies of 688076 by Market Capitalization
Companies near Sinopep-Allsino Biopharmaceutical Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to Sinopep-Allsino Biopharmaceutical Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Sinopep-Allsino Biopharmaceutical Co. Ltd. A Historical Marketcap From 2021 to 2026
Between 2021 and today, Sinopep-Allsino Biopharmaceutical Co. Ltd. A's market cap moved from $1.75 Billion to $ 1.38 Billion, with a yearly change of -16.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.38 Billion | -14.91% |
| 2025 | CN¥1.62 Billion | -27.39% |
| 2024 | CN¥2.24 Billion | +16.47% |
| 2023 | CN¥1.92 Billion | +97.02% |
| 2022 | CN¥974.68 Million | -44.18% |
| 2021 | CN¥1.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sinopep-Allsino Biopharmaceutical Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.38 Billion USD |
| MoneyControl | $1.38 Billion USD |
| MarketWatch | $1.38 Billion USD |
| marketcap.company | $1.38 Billion USD |
| Reuters | $1.38 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.